University of South Alabama
 

Search Results - Cancer Therapeutics

8 Results Sort By:
Nanoparticles as Skin Cancer Chemopreventive Agents
OPPORTUNITY Sunscreens are considered an over-the-counter drug and are regulated by the FDA. Sunscreen is used for the protection of UV radiation contained in sunlight. Over the past several years, awareness of skin cancers caused by sunlight has increased, and more attention is being paid to the importance of sunscreen and how it works. The Americ...
Inventor(s): Ajay Singh, Seema Singh, Sumit Arora
Category(s): Cancer Therapeutics, Personal Care & Cosmetics, All Technologies
Expression of Merlin Protein as a Predictive Marker for Breast Cancer Diagnosis
OPPORTUNITY The American Cancer Society’s estimates for breast cancer in the United States in 2017 that about 253,000 new cases of invasive breast cancer will be diagnosed in women. About 63,000 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is noninvasive and is the earliest form of breast cancer), and about 41,000 women will di...
Inventor(s): Lalita ShevdE-Samant, Rajeev Samant, Madhuri Mulekar, J. Allan Tucker
Category(s): Cancer Therapeutics, Biomarkers, Screening Tests, All Technologies
XRCC1 as a Predictive Biomarker for Radiation Responsiveness in Patients with Prostate Cancer
OPPORTUNITY According to statistics from the American Cancer Society, prostate cancer is the second most common cancer in American men, next to skin cancer. In 2018, it is estimated that 164,690 people will be diagnosed and about 29,430 people will die of prostate cancer. About 1 man in 9 will be diagnosed with prostate cancer during his lifetime....
Inventor(s): Eddie Reed
Category(s): Biomarkers, Cancer Therapeutics, Screening Tests, All Technologies
Methods and Compositions for Ameliorating Pancreatic Cancer
OPPORTUNITY According to statistics from the American Cancer Society, in the United States, an estimated 54,000 (28,000 men and 26,000 women) will be diagnosed and about 43,000 people (22,000 men and 21,000 women) will die of pancreatic cancer in 2017. Pancreatic cancer accounts for about 3% of all cancers in the Unite States and about 7% of all ca...
Inventor(s): Ajay Singh, Seema Singh
Category(s): Biomarkers, Cancer Therapeutics, Screening Tests, All Technologies
c-Myb Inhibition for Treatment of Prostate Cancer via RNA Therapeutics
OPPORTUNITY Prostate cancer is the most frequently diagnosed cancer in men and is an extremely heterogeneous disease, indicating that multiple genes can cause or contribute to the condition. In 2018, it is estimated that 164,690 people will be diagnosed and about 29,430 people will die of prostate cancer. About 1 man in 9 will be diagnosed with pro...
Inventor(s): Ajay Singh, Seema Singh, Sanjeev Srivastava
Category(s): Biomarkers, Cancer Therapeutics, All Technologies
Inhibition of Gli1 Increases Sensitivity to Cisplatin
OPPORTUNITY Platinum-based anticancer agents are among the most widely used agents in clinical oncology. Nucleotide excision repair (NER) is the pathway through which platinum–DNA damage is repaired and, ERCC1 is a useful biomarker for the NER process in human cells. Understanding the molecular and pharmacological control of NER may allow for...
Inventor(s): Eddie Reed, Rajeev Samant
Category(s): Cancer Therapeutics, DNA Repair Therapeutics, All Technologies
Neoadjuvant Chemotherapeutic Regimen for the Treatment of Multiple Cancer Types
OPPORTUNITY The American Cancer Society estimates that in 2017, approximately 253,000 women will be diagnosed with breast cancer in the United States, and about 41,000 women will die from breast cancer. Breast cancer is the second leading cause of cancer death in women. The chance that a woman will die from breast cancer is about 1 in 37 (or about ...
Inventor(s): Hung Khong
Category(s): Cancer Therapeutics, All Technologies
Method for Screening Anti-Cancer Compounds and Detecting Cancer in Mammals
OPPORTUNITY The global market for cancer therapeutics is enormous and predicted to reach $100.6 billion in 2018 with the total revenue for the sale of anti-cancer drugs expected to continue to rise until 2022. North America dominates the industry controlling over one third of the total market share. The market comprises various classes of compounds...
Inventor(s): Gary Piazza
Category(s): Cancer Therapeutics, Screening Tests, All Technologies